HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kraft, S. Articles by Goodman, S. L. Search for Related Content PubMed PubMed Citation Articles by Kraft, S. Articles by Goodman, S. L. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 4, 1979-1985, January 22, 1999

Definition of an Unexpected Ligand Recognition Motif for v6 Integrin^*

Sabine Kraft, Beate Diefenbach, Raj Mehta^§, Alfred Jonczyk^¶, G. Albrecht Luckenbach, and Simon L. Goodman

From the Departments of  Biomedical Research Immunology/Oncology and ^¶ Medicinal Chemistry, Merck KGaA, Darmstadt 64271, Germany and ^§ Merck London, Medical Research Council Collaborative Centre, 1-3 Burtonhole Lane, Mill Hill, London NW7 1AD, United Kingdom

	ABSTRACT

Top Abstract Introduction References

Integrin interactions with extracellular matrix proteins are mediated by brief oligopeptide recognition sequences, and synthetic peptides containing such sequences can inhibit integrin binding to the matrix. The RGD peptide motif is recognized by many integrins including v6, a specific receptor for fibronectin thought to support epithelial cell proliferation during wound healing and carcinoma progression. We report here the discovery of an unexpected non-RGD recognition motif for integrin v6. We compared the recognition profiles of recombinant v6 and v3 integrins by using phage display screening employing 7-mer and 12-mer peptide libraries. As predicted, phages binding strongly to v3 contained ubiquitous RGD sequences. However, on v6, in addition to RGD- containing phages, one-quarter of the population from the 12-mer library contained the distinctive consensus motif DLXXL. A synthetic DLXXL peptide, RTDLDSLRTYTL, selected from the phage sequences (clone-1) was a selective inhibitor of RGD-dependent ligand binding to v6 in isolated receptor assays (IC₅₀ = 20 nM), and in cell adhesion assays (IC₅₀ = 50 µM). DLXXL peptides were highly specific inhibitors of v6-fibronectin interaction as synthetic scrambled or reversed DLXXL peptides were inactive. NH₂- and COOH-terminal modifications of the flanking amino acids suggested that the preceding two and a single trailing amino acid were also involved in interaction with v6. The DLXXL sequence is present in several matrix components and in the  chain of many integrins. Although there is as yet no precise biological role known for DLXXL, it is clearly a specific inhibitory sequence for integrin v6 which has been unrecognized previously.

	INTRODUCTION

Top Abstract Introduction References

Integrins are a family of heterodimeric class I transmembrane receptors involved in numerous cell-matrix and cell-cell adhesion phenomena (1). They can be grouped roughly into three classes: the 1 series, which are ubiquitous receptors for extracellular matrix (2); the 2 series, which are activatable on leukocytes and are triggered during the inflammatory response (3); and the v series, which bind and mediate the cell response to provisional extracellular matrices found during wound repair and other pathological processes (4).

The integrins 51 (5), IIb3 (6), 81 (7), v1 (8), v3 (9), and v6 (10) all bind the Arg-Gly-Asp- (RGD) peptide sequence in fibronectin, where it is presented in a constrained loop (11). Soluble RGD-containing peptides can inhibit the interaction of each of these integrins with fibronectin. However, to analyze the function of individual fibronectin receptors in a particular cellular environment it is useful to have more specific inhibitors, and a variety of inhibitory antibodies, modified peptides, and non-peptidic substances has been developed. However, as yet no inhibitor has been discovered specific for v6. v6 is a rare integrin, induced during repair processes in epithelia (10, 12). Its only known specificities are for fibronectin (10), where it can be the dominant receptor mediating cell adhesion (13), and for tenascin (14). v6 is believed to be involved in supporting the proliferation of epithelia during repair processes (15), and it can promote the proliferation of carcinoma cells (16).

Phage display technology has proved useful for identifying novel specific peptide sequences that act as ligand mimetics (17, 18). Accordingly, both constrained cyclic and linear peptide libraries have been used to discover novel peptides that interact with integrins (19-23). But, with few exceptions, these peptides contain RGD sequences, whereas the non-RGD sequences found have only bound weakly.

Here we have used recombinant v6 expressed as a transmembrane truncated soluble receptor to screen phage libraries displaying peptides of 7 or 12 amino acids. This revealed a strong and previously unpredicted recognition motif for v6 integrin which we describe here. Similar motifs are displayed in several extracellular matrix molecules.

	EXPERIMENTAL PROCEDURES

Ligands-- The ligands fibronectin (24), vitronectin (25), and fibrinogen (26) were purified from human blood and biotinylated as described previously (27, 28).

Preparation of Integrins-- Human integrins were extracted from native sources (v5, IIb3) or expressed as recombinant soluble receptors using the baculovirus expression system (v3, v6).

IIb3 was prepared from outdated human platelet concentrates (6) as detailed previously (27) by affinity chromatography on GRGDSPK-conjugated Sepharose CL-4B. The column was eluted with the GRGDSPK, the peak containing IIb3 was concentrated ~5-fold, dialyzed, and stored at 80 °C.

v5 was purified from human placenta (29). Term placenta was minced in ~2 volumes of ice-cold solution A (0.05% w/v digitonin, 2 mM CaCl₂, 2 mM Pefabloc (Merck), pH 7.4), then washed twice in solution A by centrifugation (12,000 × g_max, 45 min, 4 °C) and resuspension. The final pellet was extracted by resuspension in ~4 volumes of ice-cold buffer B (100 mM octyl -D-glucopyranoside, 1 mM CaCl_2, 2 mM Pefabloc, in phosphate-buffered saline) and centrifuged (12,000 g_max, 45 min, 4 °C). The supernatant was recirculated over a P1F6 antibody column (16 h, 4 °C) (13). After washing with buffer C (0.1% Nonidet P-40 in phosphate-buffered saline; ~10 bed volumes) and buffer D (0.1% Nonidet P-40, 2 mM CaCl₂, 10 mM sodium acetate, pH 4.5; ~10 cv), bound material was eluted with buffer E (buffer D adjusted to pH 3.1). The eluant was neutralized with 3 M Tris, pH 8.8, dialyzed against buffer C, and concentrated ~10× using Aquacide II (Calbiochem). The purified receptor was stored at 80 °C.

v3 was purified in a soluble transmembrane truncated form from a baculovirus expression system as detailed previously (28) with minor modifications using 14D9.F8 antibody affinity chromatography (27). Briefly, the extracellular domains of v and 3 human integrin chains were cloned into the pBacPAK expression system, the resulting recombinant baculoviruses containing both chains were used to coinfect High Five insect cells, and the soluble receptor was harvested from the culture supernatant at 48-72 h of culture by passing the supernatant over 14D9.F8 antibody affinity columns, washing, and eluting at pH 3.1. Peak fractions were neutralized, concentrated, and dialyzed before shock freezing and storage at 80 C. The soluble human receptor (v3-TM) had ligand binding specificities indistinguishable from the native receptor isolated from placenta (27).

v6 was purified in a soluble transmembrane truncated form (13) from a baculovirus expression system as detailed previously for v3 (28) using 14D9.F8 antibody affinity chromatography (27). The 6 cDNA clone pCDNAneo6 was the generous gift of Dr. D. Sheppard (University of California, San Francisco). The procedure and the cloning will be detailed elsewhere.¹ In brief, the transfer vector pAcUW31 (CLONTECH Laboratories, Inc.) allowed simultaneous expression of two different target cDNAs and was used to make recombinant baculovirus-expressing transmembrane truncated v6. The preparation of truncated v transfer vectors was as described (28). Transmembrane truncated v was excised from v-TM(pBac9) (28) using EcoRI and XbaI and cloned into the EcoRI site of pAcUW31 downstream of the polyhedrin promoter by blunt end ligation. Transmembrane truncated 6 cDNA was excised from pCDNAneo6 (13) using EcoRI and XbaI and cloned into the BamHI site of pAcUW31 downstream of the polyhedrin promoter by blunt end ligation. The tandem vectors containing truncated v and truncated 6 were used to prepare recombinant baculovirus as described (28). The recombinant baculoviruses were used to infect High Five insect cells, and the soluble receptor was harvested from the culture supernatant at 48-72 h of culture by passing the supernatant over 14D9.F8 antibody affinity columns, washing, and eluting at pH 3.1. All processes were carried out at room temperature and in the absence of detergents. Peak fractions were neutralized, concentrated, and dialyzed at 4 °C before shock freezing and storage at 80 °C. The recombinant soluble human receptor (v6-TM) is biologically active and retains ligand specificity (13).

The integrin v3-TM, v5, and v6-TM preparations were ~95% pure as judged by anti-integrin ELISA² using  and  chain-specific monoclonal antibodies (data not shown) and by SDS-polyacrylamide gel electrophoresis against molecular weight standards (Bio-Rad).

Peptides-- Peptides were synthesized, purified, and analyzed in-house as described (30) using an Fmoc (N-(9-fluorenyl)methoxycarbonyl) strategy with acid-labile side chain protection on acid-labile Wang resin using a commercially available continuous flow peptide synthesizer (Milligen 9050 plus). Purification was done by reversed phase HPLC and analysis by HPLC and fast atom bombardment-mass spectrometry. The peptide EMD 66203, cyclic(Arg-Gly-Asp-(D-Phe)-Val), is abbreviated as c(RGDfV).

Antibodies-- 17E6 and 14D9.F8 (anti-v), LM609 (anti-v3), P4C10 (anti-1), and P1F6 (anti-v5) all inhibit cell adhesion mediated by their respective integrins and have been described in detail elsewhere (27).

Selection of Integrin-binding Phages-- M13 phage display libraries displaying linear peptides of 7 or 12 amino acids (PHD system from New England Biolabs) were used to select integrin-binding phages. Panning was performed as described in the product manual with the following modifications. Integrins were diluted to 1.5 µg/ml in TBS++ (1 mM CaCl₂, 1 mM MgCl₂, 0.01 mM MnCl₂, 150 mM NaCl, 50 mM Tris, pH 7.4) and adsorbed onto Petri dishes for 16 h at 4 °C. After blocking for 2 h with 0.5% BSA in TBS++, aliquots of the phage display libraries (10¹¹ plaque-forming units) were diluted in TBS++ containing 0.1% Tween 20, and phages were allowed to bind for 1 h at 30 °C. Unbound phages were removed by washing with TBS++ containing 0.3% Tween 20, and bound phages were eluted with 0.1 M glycine, pH 2.2, and amplified in Escherichia coli XL-1. Phages were prepared from the culture supernatant by standard polyethylene glycol/NaCl precipitation and used for the next round of panning. After the third round of panning randomly selected phage plaques were amplified, and single-stranded DNA was sequenced using the Amplitaq FS sequencing kit (Applied Biosystems) with the primer 96gIII (New England Biolabs).

Phage Binding Assay-- Integrins were adsorbed onto 96-well plates as described above for the Petri dishes. Phages amplified from single plaques and purified by polyethylene glycol/NaCl precipitation were serially diluted in TBS++ containing 0.1% Tween 20 and 0.1% BSA and allowed to bind to integrins for 1 h. After washing, bound phages were detected with an anti-M13 horseradish peroxidase-conjugated antibody (Amersham Pharmacia Biotech) and 3,3',5,5'- tetramethylbenzidine substrate.

Integrin Adsorption Control-- The adsorption of the integrins to the plates was investigated using indirect ELISA. Integrins were immobilized by adsorption on 96-well plates, and the plates were blocked with BSA as described under "Selection of Integrin-binding Phages" (above). 17E6 antibody, specific for the v chain of all v integrins (27), was biotinylated (28), titrated in phage diluent buffer (0.1% Tween 20, 0.1% BSA, TBS++), and allowed to bind (1 h, 37 °C); after washing (0.3% Tween 20 and TBS++), bound antibody was detected with anti-biotin alkaline phosphatase conjugate (Bio-Rad) and p-nitrophenyl phosphate substrate.

Integrin-Ligand Competition Assays-- Integrin-ligand competition assays were performed as described (30). Integrins were immobilized as described under "Selection of Integrin-binding Phages" (above). Serially diluted peptides in TBS++ containing 0.1% BSA were added in parallel with biotinylated fibronectin, vitronectin, or fibrinogen (to 1 µg/ml). After a 3-h incubation at 37 °C and washing with TBS++, bound ligand was detected by incubation with an anti-biotin alkaline phosphatase-conjugated antibody (Bio-Rad) followed by development with a p-nitrophenyl phosphate substrate. The reaction was stopped by the addition of NaOH and the color intensity read at 405 nm. The optimal time course for the integrin-ligand interaction was determined in preliminary experiments.

Inverted Integrin-Ligand Competition Assay-- v6-TM was biotinylated as described previously for matrix proteins and antibodies (28). Fibronectin was diluted (to 5 µg/ml) in TBS++ and immobilized by adsorption to 96-well plates for 16 h at 4 °C as described under "Selection of Integrin-binding Phages" (above). After blocking for 2 h with 0.5% BSA in TBS++ (BTBS++) and washing in TBS, biotinylated integrin (3 µg/ml in BTBS++) was added in the presence of peptides serially diluted in the same buffer. After incubation (3 h, 37 °C) and washing with TBS++, bound integrin was detected by incubation with anti-biotin alkaline phosphatase-conjugated antibody and color development as described above.

Cell Attachment Assays-- Cell culture of lines M21-L and HT-29, and their use in cell attachment assays, has been described in detail elsewhere (27, 31). M21-L is a human melanoma cell line selected for null expression of v integrins (32) which uses only 51 to attach to fibronectin. HT-29 is a human carcinoma cell line that uses only v6 integrin to attach to fibronectin (33). The integrin profile of the cells was monitored routinely by fluorescence-activated cell sorter and showed the expected lack of v integrins on M21-L and the lack of 51 and v3 on HT-29 (see also Fig. 6). 96-well plates were coated with fibronectin (12.5 µg/ml) and blocked with BSA. Serially diluted peptides or antibodies were added followed by cells (2.5 × 10⁴ cells/well). After 1.5 h at 37 °C nonadherent cells were washed away and attached cells detected using an assay measuring cellular hexosaminidase activity (31).

	RESULTS

Recombinant soluble human integrins v3 and v6 and native placental v5 and platelet IIb3 were purified by antibody or ligand affinity chromatography. On SDS gels each preparation showed the two major bands corresponding to the  and the  chains (Fig. 1A). The chains migrated at the molecular mass predicted for the intact and transmembrane truncated recombinant chains (v full-length, 150 kDa; v-TM, 125 kDa; IIb full-length, 145 kDa; 3 full-length, 105 kDa; 5 full-length, 100 kDa; 3-TM, 85 kDa; 6-TM, 90 kDa). Each integrin was biologically active and showed ligand binding and divalent cation requirements predicted from the literature and also as demonstrated independently by us (13, 27, 28, 30).

View larger version (20K): [in this window] [in a new window]   Fig. 1.   Integrin preparation and adsorption. Panel A, SDS-polyacrylamide gel electrophoresis (7.5% gel) under nonreducing conditions of transmembrane truncated recombinant v3 (lane 1), placental v5 (lane 2), transmembrane truncated recombinant v6 (lane 3), and platelet IIb3 (lane 4). The gel is stained with Coomassie Blue. Arrowheads and numbers to the right indicate the migration position of marker proteins and their molecular mass in kDa. The band at ~65 kDa in lane 4 may be a serum albumin contaminant. Panel B, adsorption control. Integrins v3-TM (solid circles), v6-TM (open circles), and v5 (solid triangles down) were adsorbed to 96-well plates from 1.5-µg/ml solutions and blocked as for phage display screens and ligand competition assays. Biotinylated antibody 17E6 (27), serially diluted as indicated, was added, and after incubation and washing bound antibody was detected with anti-biotin-alkaline phosphatase conjugate. The non-v integrin control, IIb3, gave background binding of 17E6 (A405 < 0.05) (data not shown).

Recombinant v6 expressed as a transmembrane truncated soluble receptor bound two distinct classes of phages in phage display panning experiments from a linear 12-mer library as determined from the sequences of more than 100 clones: those containing RGD sequences (51%) and those containing an XXDLXXLX motif (27%). Some phages contained RGD and also continued with the motif as RGDLXXL (9%), whereas others displayed the sequence RGDL (38%); the remaining phages that were bound often contained DLXXL-related sequences. A selection of representative displayed sequences is shown (Table I).

View this table: [in this window] [in a new window]   Table I Integrin binding clones from phage display library screens Representative displayed peptide sequences from clones isolated by low pH elution from recombinant v6 and v3. Sequences have been selected to approximate the distribution of features found. RGD sequences have been underlined and DLXXL sequences highlighted bold and underlined.

In the non-RGD sequences, the amino acid distribution at X within X¹X²DLX³X⁴LX⁵ appeared nonrandom. Arg was favored at X¹ and X⁵, Thr/Ser/Asp/Gly at X², whereas at X³X⁴ Ser/Thr were often paired with a charged amino acid. These characteristics were typified by a dominant clone with the sequence RTDLDSLRTYTL (clone-1). Non-RGD, DLXXL-containing peptides were represented in only 5% of clones isolated from a 7-mer phage display library, suggesting that sequences COOH-terminal to DLXXL are also involved in integrin binding (Table I). Indeed, the sequence COOH-terminal to the peptide insertion site in the phage pIII protein continues Gly-Gly-Gly (i.e. the 7-mer library inserts would read XXDLXXLGGG), and related sequences were not isolated from the 12-mer library. Pro at X³X⁴ was never found in a DLXXL motif, and it was similarly excluded from the 4 amino acids COOH-terminal of the DLXXL sequence, although not from these positions in RGD-containing sequences. One sequence was found where the motif was concatenated as GDLDLLKLRLTR. To investigate whether the presence of DLXXL sequences was a library artifact, we also screened on v3. Here mainly RGD-containing phages were bound, the DLXXL sequence was absent, and RGDL was present in fewer than 10% of clones. This distribution was distinct from that of the v6 phage display library screen (Table I) and similar to that reported for linear 15-mer library screens (23).

To eliminate the possibility that the differences in phage interactions seen between v3 and v6 were artifacts caused by differential adsorption of integrins during the phage screen, we estimated the amounts of each integrin adsorbed to the screening plates under the conditions of the screen using an indirect ELISA technique (Fig. 1B). The ELISA titration curves derived using the 17E6 antibody, which recognizes the v chain, were similar in form, in saturation level of antibody binding, and in the amount of antibody needed to titrate 50% of the receptors. This indicated that similar amounts of the v integrins were adsorbed to the plates.

To test the specificity of interaction of phage clones we used a quantitative ELISA to measure the binding of representative phages from the v6 screen to immobilized purified integrins (Fig. 2). DLXXL-containing phages bound only to v6, whereas RGD phages bound both v6 and v3 and weakly to v5 and to IIb3. This indicated that the XXDLXXLX clones isolated in the screen were specific for v6.

View larger version (32K): [in this window] [in a new window]   Fig. 2.   Binding to integrins of phages displaying different peptides. Phage binding to immobilized integrins was detected using an anti-M13 antibody. Phages displaying RTDLDSLRTYTL (solid circles), GDLDLLKLRLTR (solid squares), RGDAPSPNIFRL (triangles up), QSAHRGDIPNVL (triangles down) binding to v6 (panel A), v3 (panel B), v5 (panel C), IIb3 (panel D). Note that the DLXXL-containing phages bind only v6.

RGD-containing peptides inhibit the interaction of RGD-containing ligands with their integrin receptors. To test whether DLXXL peptides were able to inhibit integrin-ligand interaction, we synthesized the clone-1 peptide. We compared the effects of clone-1 peptide and RGD-containing peptides on ligands binding to integrins v3, v5, and v6 (Fig. 3). The clone-1 peptide specifically inhibited fibronectin binding to v6 with an IC₅₀ of 20 nM but did not affect ligand binding to v3, v5, or IIb3 (IC₅₀ > 50 µM). By contrast, the peptide GRGDSPK inhibited ligand binding to all four integrins with IC₅₀  1 µM. A cyclic peptide inhibitor c(RGDfV) showed specificity for v3 (IC₅₀ = 10 nM) over v6 and IIb3 (IC₅₀  1 µM). v3 also binds to fibronectin. To test whether the effects of DLXXL peptides were a result of the ligand used with v6, fibronectin, we also examined the effect of clone-1 peptide on fibronectin binding to v3 (Fig. 4). The DLXXL peptide also had no effect on fibronectin binding, whereas the GRGDSPK peptide inhibited (IC₅₀ = 200 nM). Thus, the results for vitronectin and fibronectin on v3 were similar.

View larger version (37K): [in this window] [in a new window]   Fig. 3.   Effect of peptides on integrin-ligand interaction. Biotinylated ligand binding to immobilized integrins in the presence of peptides was detected using an anti-biotin antibody. Values were converted to percentage of control (no peptide). Solid circles, RTDLDSLRTYTL; open circles, GRGDSPK; open squares, c(RGDfV); open diamonds, AGDV. Panel A, fibronectin binding to v6; panel B, vitronectin binding to v3; panel C, vitronectin binding to v5; panel D, fibrinogen binding to IIb3.

View larger version (21K): [in this window] [in a new window]   Fig. 4.   Effect of peptides on fibronectin binding to v3. Fibronectin binding to v3 was measured in the presence of increasing amounts of RTDLDSLRTYTL (solid circles) or GRGDSPK (open circles). Values were converted to percentage of control (no peptide).

We also examined whether the assay geometry was producing an artifactual binding of DLXXL to v6. In vivo, v6 binds to insoluble fibronectin in the extracellular matrix rather than to the soluble form used in the receptor assay here. In addition, adsorption to plastic might change the conformation of the v6 integrin and so alter its specificity. We therefore tested the effect of DLXXL peptides on v6 binding to immobilized fibronectin (Fig. 5). Once again, the RTDLDSLRTYTL peptide strongly inhibited the v6-fibronectin interaction (IC₅₀ = 100 nM). Both c(RGDfV) and GRGDSPK peptides were also effective in this assay configuration. Thus, the effect of DLXXL peptide on v6 was probably not an artifact of integrin adsorption to plastic.

View larger version (23K): [in this window] [in a new window]   Fig. 5.   Inverted integrin-ligand competition assay. Biotinylated v6-TM binding to fibronectin was detected in the presence of the indicated concentrations of test peptides. Bound integrin was detected with anti-biotin antibody. Solid circles, RTDLDSLRTYTL; open circles, GRGDSPK; open squares, c(RGDfV); open diamonds, AGDV.

Clone-1 peptides were also tested in cell attachment assays. HT-29 carcinoma cell attachment to fibronectin was strongly inhibited by clone-1 peptide and by GRGDSPK (Fig. 6A). This attachment was also suppressed completely by the 17E6 (anti-v) antibody, showing that it was dependent on v integrins. HT-29 attachment to fibronectin has been shown to be mediated by v6. M21-L melanoma cells attached to fibronectin, and this was inhibited by GRGDSPK but was little affected by the clone-1 peptide (Fig. 6B). M21-L attachment was suppressed by either P4C10 (anti-1) or P1D6 (anti-5) antibodies, indicating that it was mediated by the 51 integrin. Together, these data indicated that the peptide displayed by clone-1 was an active and specific inhibitor of v6 independent of the RGD sequence.

View larger version (21K): [in this window] [in a new window]   Fig. 6.   Effect of peptides on cell attachment to fibronectin. Cell attachment on fibronectin of HT-29 cells (panel A) and M21-L cells (panel B) in the presence of peptides and inhibitory antibodies is shown. Solid circles, RTDLDSLRTYTL; open circles, GRGDSPK; open squares, 17E6 (v-inhibitory;) open triangles up, P4C10 (1-inhibitory); open triangles down, P1D6 (5-inhibitory). Values were converted to percentage of control (control cell attachment in the absence of peptide for HT-29 and M21-L was 54 and 47% of cells added, respectively). HT-29 attachment to fibronectin is dependent on v integrins. M21-L attachment to fibronectin is dependent on 51.

We next investigated which elements of the X¹X²DLX³X⁴LX⁵ motif were important for its inhibitory activity. NH₂- and COOH-terminal truncated forms of the peptide were synthesized and tested for their activity to block fibronectin binding to v6. The data are summarized in Table II. Truncation of the COOH terminus of DLXXL had little effect on inhibitory activity until the group at X⁵ was deleted, when activity diminished by 30-fold. Removal of the groups at X¹X² also abolished the activity, indicating that the core motif was the 8-amino acid sequence X¹X²DLX³X⁴LX⁵.

View this table: [in this window] [in a new window]   Table II Inhibition of fibronectin v6 interaction by synthetic DLXXL peptides Biotinylated fibronectin (FN) binding to v6 in the presence of synthetic linear peptides was detected using an anti-biotin antibody.

Although the specific selection of DLXXL sequences from a highly degenerate (2 × 10⁹ clones) display library implies specificity of interaction, we examined this more directly by investigating the effect of reversed (TRLSDLDTR) and scrambled (LDTRTRLSD) peptides on v6-fibronectin interaction. These peptides were > 4 orders of magnitude less active than the corresponding DLXXL peptide (Fig. 7).

View larger version (26K): [in this window] [in a new window]   Fig. 7.   Effect of peptides on fibronectin binding to v6. Fibronectin binding to v6 was measured in the presence of increasing amounts of RTDLDSLRTY (solid circles), RTDLYYLRTY (solid squares), RTDLYYLMDL (solid triangles), PVDLYYLMDL (solid diamonds), GRGDSPK (open circles), TRLSDLDTR (open triangles), or LDTRTRLSD (open squares).

The high specificity of the clone-1 sequence for v6 suggested that it might represent a sequence in a native v6 ligand. Indeed, a FASTA search of the GEMBL data bases revealed several extracellular matrix components with related consensus sequences (Table III) including fibrinogen  chain, tenascin, laminin 1, 3, and 1, 2, and 3 chains. With the exception of tenascin, which has been reported to bind in an RGD-dependent way to v6 (14), none of these molecules has been implicated previously as a ligand for v6, thus the possible biological relevance of such homologies remains unknown.

Interestingly, the sequence DLYYLMDL is strongly conserved in human integrin  chains and may interact directly with ligands, hinting that the clone-1 sequence might function by disturbing the interaction from the side of the receptor rather than as a ligand mimetic (e.g. like an RGD peptide). To test this possibility, we examined a synthetic DLXXL peptide sequence derived from the 6 chain, P¹³²VDLYYLMDL¹⁴¹, for its effect on fibronectin-v6 interaction (Fig. 7). Compared with the corresponding 10-mer derived from clone-1, RTDLDSLRTY, the 6 peptide was > 4 orders of magnitude less active as an inhibitor of this interaction. Once again, this supported the concept that the sequences selected from the phage display library were highly specific. We examined the structural basis of the inhibition by exchanging the flanking sequences from the clone-1 10-mer with those of the 6 DLXXL peptide. Exchange of the DLYYL core gave a highly active inhibitor, as did the core and the trailing 3 amino acids. Thus the 2 amino acids preceding the DLXXL sequence were also important for integrin inhibitory activity.

	DISCUSSION

Here, we describe the discovery by phage display screening of an unexpected binding sequence (DLXXL) for v6 integrin, which has previously been thought to interact only with RGD sequences in its target ligands. v6 is a rare inducible integrin (12, 15), and isolation from native tissue sources has not been reported. v6 has been prepared successfully by recombinant methods (13), and we have adapted this technology to produce biochemical amounts of soluble receptor.¹ As with v3 (28), we found that soluble, recombinant v6 retains the biological activity, specificity, and inhibitor profiles of the native receptor in situ, thus confirming and extending the studies of Sheppard and co-workers (13). Because the receptor is secreted into the serum-free culture supernatant, affinity purification gives rise to a very highly purified molecule with a minimal amount of other proteins¹ and thus is an excellent target for a phage display screen.

It is of interest that RGD-dependent extracellular matrix binding to v6 is inhibited strongly by peptides containing DLXXL sequences that bear no close similarity to sequences in fibronectin, although they do resemble a sequence in tenascin. DLXXL sequences have rarely been found in other phage display studies on integrins; the only clone described in the literature bearing an RGDLXXL sequence was a weak inhibitor of v3 (23).

We were able to demonstrate directly that synthetic DLXXL peptides, although strong inhibitors of v6, had minimal effects on the interaction of integrins v3, v5, and IIb3 with their ligands. Although indirect, cell adhesion assays implied that 51 was also not affected. The DLXXL sequences, therefore, represent the first specific inhibitory peptides for v6 integrin.

Analysis of the structures of phage-encoded v6-binding XXDLXXLX peptides showed that although RXDLXXL was a favored sequence, it was by no means obligatory. Phages binding to v6 were found where displayed arginine was replaced by hydroxylated, neutral, or basic residues or was absent. The inhibitory effect of DLXXL peptides is apparently not the result of nonspecific charge effects because neither reversed nor scrambled versions of highly inhibitory DLXXL peptides have significant effects on the v6-fibronectin interaction. Further structural constraints on the context of DLXXL were found in experiments to investigate the possible biological significance of the v6- DLXXL interaction. DLXXL sequences are found in seven integrin  chains (Table III), in a region directly implicated in ligand binding (34). We hypothesized that the DLXXL motif was involved in the interaction of integrin  and  chains and that the DLXXL peptide might act by interacting with a binding site on the  chain, usually occupied by  chain sequences, so disrupting integrin function. To test this, we examined a 10-mer peptide corresponding to a DLXXL sequence in the 6 chain. It was inactive, indicating that the DLXXL peptides were not acting by competing for 6 chain binding sites on the v chain. However, the study did reveal that the context of the DLXXL sequence was crucial because appropriate NH₂-terminal flanking amino acids were critical for inhibitory activity, whereas those in the COOH-terminal flanking region were less crucial.

At present we have no indication where, if at all, the XXDLXXLX sequences play a biological role with v6 integrin. As discussed previously for the CRRETAWAC inhibitory peptide sequence for 51 (21), XXDLXXLX may bind a site distinct from the RGD site and act as an allosteric inhibitor of RGD-ligand binding. But in the absence of kinetic data at present we believe that the XXDLXXLX sequences are ligand mimetics. Similar inhibitory mimetic binding sequences with no homology to known ligands are found in the phage display literature (35, 36). The unusual strong and specific inhibitory binding sequences that we characterize here provide a unique pharmacological tool from which to investigate v6 biological function further.

	ACKNOWLEDGEMENTS

We thank E. Rosell (Merck LBI) for discussion and introduction to the phage display technology, D. Sheppard (UCSF) for discussion and access to 6 cDNA, and R. Dunker and I. Remitschka (Merck, kGaA) for biotechnological support.

	FOOTNOTES

^* This work was funded in part by Bundesministerium für Bildung und Forschung Project 0310767.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 49-6151-726-452; Fax: 49-6151-729-0452; E-mail: goodman{at}merck.de.

The abbreviations used are: ELISA, enzyme-linked immunosorbent assay; HPLC, high performance liquid chromatography; BSA, bovine serum albumin.

¹ B. Diefenbach, R. J. Mehta, A. Brown, E. Cullen, J. Adams, D. Sheppard, R. Dunker, S. L. Goodman, and D. Güssow, manuscript in preparation.

	REFERENCES

Top Abstract Introduction References

1. Tuckwell, D. S., Weston, S. A., and Humphries, M. J. (1993) Symp. Soc. Exp. Biol. 47, 107-136[Medline] [Order article via Infotrieve]
2. Ruoslahti, E., Noble, N. A., Kagami, S., and Border, W. A. (1994) Kidney Int. Suppl. 44, S17-S22[Medline] [Order article via Infotrieve]
3. Gahmberg, C. G., Tolvanen, M., and Kotovuori, P. (1997) Eur. J. Biochem. 245, 215-232[Medline] [Order article via Infotrieve]
4. Marshall, J. F., and Hart, I. R. (1996) Semin. Cancer Biol. 7, 129-138[CrossRef][Medline] [Order article via Infotrieve]
5. Pytela, R., Pierschbacher, M. D., and Ruoslahti, E. (1985) Cell 40, 191-198[CrossRef][Medline] [Order article via Infotrieve]
6. Pytela, R., Pierschbacher, M. D., Ginsberg, M. H., Plow, E. F., and Ruoslahti, E. (1986) Science 231, 1559-1562[Abstract/Free Full Text]
7. Schnapp, L. M., Hatch, N., Ramos, D. M., Klimanskaya, I. V., Sheppard, D., and Pytela, R. (1995) J. Biol. Chem. 270, 23196-23202[Abstract/Free Full Text]
8. Vogel, B. E., Tarone, G., Giancotti, F. G., Gailit, J., and Ruoslahti, E. (1990) J. Biol. Chem. 265, 5934-5937[Abstract/Free Full Text]
9. Charo, I. F., Nannizzi, L., Smith, J. W., and Cheresh, D. A. (1990) J. Cell Biol. 111, 2795-2800[Abstract/Free Full Text]
10. Busk, M., Pytela, R., and Sheppard, D. (1992) J. Biol. Chem. 267, 5790-5796[Abstract/Free Full Text]
11. Leahy, D. J., Aukhil, I., and Erickson, H. P. (1996) Cell 84, 155-164[CrossRef][Medline] [Order article via Infotrieve]
12. Breuss, J. M., Gillett, N., Lu, L., Sheppard, D., and Pytela, R. (1993) J. Histochem. Cytochem. 41, 1521-1527[Abstract]
13. Weinacker, A., Chen, A., Agrez, M., Cone, R. I., Nishimura, S., Wayner, E., Pytela, R., and Sheppard, D. (1994) J. Biol. Chem. 269, 6940-6948[Abstract/Free Full Text]
14. Prieto, A. L., Edelman, G. M., and Crossin, K. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10154-10158[Abstract/Free Full Text]
15. Breuss, J. M., Gallo, J., DeLisser, H. M., Klimanskaya, I. V., Folkesson, H. G., Pittet, J. F., Nishimura, S. L., Aldape, K., Landers, D. V., Carpenter, W., et al.. (1995) J. Cell Sci. 108, 2241-2251[Abstract]
16. Agrez, M., Chen, A., Cone, R. I., Pytela, R., and Sheppard, D. (1994) J. Cell Biol. 127, 547-556[Abstract/Free Full Text]
17. Scott, J. K., and Smith, G. P. (1990) Science 249, 386-390[Abstract/Free Full Text]
18. Devlin, J. J., Panganiban, L. C., and Devlin, P. E. (1990) Science 249, 404-406[Abstract/Free Full Text]
19. O'Neil, K. T., Hoess, R. H., Jackson, S. A., Ramachandran, N. S., Mousa, S. A., and DeGrado, W. F. (1992) Proteins 14, 509-515[CrossRef][Medline] [Order article via Infotrieve]
20. Koivunen, E., Gay, D. A., and Ruoslahti, E. (1993) J. Biol. Chem. 268, 20205-20210[Abstract/Free Full Text]
21. Koivunen, E., Wang, B., and Ruoslahti, E. (1994) J. Cell Biol. 124, 373-380[Abstract/Free Full Text]
22. Koivunen, E., Wang, B., and Ruoslahti, E. (1995) Bio/Technology 13, 265-270[CrossRef][Medline] [Order article via Infotrieve]
23. Healy, J. M., Murayama, O., Maeda, T., Yoshino, K., Sekiguchi, K., and Kikuchi, M. (1995) Biochemistry 34, 3948-3955[CrossRef][Medline] [Order article via Infotrieve]
24. Ruoslahti, E., Hayman, E. G., Pierschbacher, M., and Engvall, E. (1982) Methods Enzymol. 82, 803-831
25. Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M. (1988) Cell Struct. Funct. 13, 281-292[CrossRef][Medline] [Order article via Infotrieve]
26. Kazal, L. A., Ansel, S., Miller, O. P., and Tocantins, L. M. (1963) Proc. Soc. Exp. Biol. Med. 113, 989-994
27. Mitjans, F., Sander, D., Adan, J., Sutter, A., Martinez, J. M., Jaggle, C. S., Moyano, J. M., Kreysch, H. G., Piulats, J., and Goodman, S. L. (1995) J. Cell Sci. 108, 2825-2838[Abstract]
28. Mehta, R. J., Diefenbach, B., Brown, A., Cullen, E., Jonczyk, A., Güssow, D., Luckenbach, G. A., and Goodman, S. L. (1998) Biochem. J. 330, 861-869
29. Smith, J. W., Vestal, D. J., Irwin, S. V., Burke, T. A., and Cheresh, D. A. (1990) J. Biol. Chem. 265, 11008-11013[Abstract/Free Full Text]
30. Haubner, R., Gratias, R., Diefenbach, B., Goodman, S. L., Jonczyk, A., and Kessler, H. (1996) J. Am. Chem. Soc. 118, 7461-7472[CrossRef]
31. Goodman, S. L., Deutzmann, R., and von der Mark, K. (1987) J. Cell Biol. 105, 589-598[Abstract/Free Full Text]
32. Cheresh, D. A., and Spiro, R. C. (1987) J. Biol. Chem. 262, 17703-17711[Abstract/Free Full Text]
33. Kemperman, H., Wijnands, Y. M., and Roos, E. (1997) Exp. Cell Res. 234, 156-164[CrossRef][Medline] [Order article via Infotrieve]
34. Liu, Y. K., Nemoto, A., Feng, Y., and Uemura, T. (1997) J. Biochem. (Tokyo) 121, 961-968[Abstract/Free Full Text]
35. Sahu, A., Kay, B. K., and Lambris, J. D. (1996) J. Immunol. 157, 884-891[Abstract]
36. Wrighton, N. C., Farrell, F. X., Chang, R., Kashyap, A. K., Barbone, F. P., Mulcahy, L. S., Johnson, D. L., Barrett, R. W., Jolliffe, L. K., and Dower, W. J. (1996) Science 273, 458-464[Abstract]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. DiCara, A. Burman, S. Clark, S. Berryman, M. J. Howard, I. R. Hart, J. F. Marshall, and T. Jackson Foot-and-Mouth Disease Virus Forms a Highly Stable, EDTA-Resistant Complex with Its Principal Receptor, Integrin {alpha}v 6: Implications for Infectiousness J. Virol., February 1, 2008; 82(3): 1537 - 1546. [Abstract] [Full Text] [PDF]

				T.-Y. Lee, C.-T. Lin, S.-Y. Kuo, D.-K. Chang, and H.-C. Wu Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery Cancer Res., November 15, 2007; 67(22): 10958 - 10965. [Abstract] [Full Text] [PDF]

				S. H. Hausner, D. DiCara, J. Marik, J. F. Marshall, and J. L. Sutcliffe Use of a Peptide Derived from Foot-and-Mouth Disease Virus for the Noninvasive Imaging of Human Cancer: Generation and Evaluation of 4-[18F]Fluorobenzoyl A20FMDV2 for In vivo Imaging of Integrin {alpha}v{beta}6 Expression with Positron Emission Tomography Cancer Res., August 15, 2007; 67(16): 7833 - 7840. [Abstract] [Full Text] [PDF]